WO2021200808A1 - 抗ウイルス剤 - Google Patents

抗ウイルス剤 Download PDF

Info

Publication number
WO2021200808A1
WO2021200808A1 PCT/JP2021/013255 JP2021013255W WO2021200808A1 WO 2021200808 A1 WO2021200808 A1 WO 2021200808A1 JP 2021013255 W JP2021013255 W JP 2021013255W WO 2021200808 A1 WO2021200808 A1 WO 2021200808A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
antiviral
antiviral agent
test
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/013255
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
義晃 加藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SC Environmental Science Co Ltd
Original Assignee
SC Environmental Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SC Environmental Science Co Ltd filed Critical SC Environmental Science Co Ltd
Priority to JP2022512202A priority Critical patent/JP7748103B2/ja
Publication of WO2021200808A1 publication Critical patent/WO2021200808A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P3/00—Fungicides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D201/00—Coating compositions based on unspecified macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
    • C09D5/14—Paints containing biocides, e.g. fungicides, insecticides or pesticides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D7/00—Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
    • C09D7/40—Additives
    • C09D7/60—Additives non-macromolecular
    • C09D7/63—Additives non-macromolecular organic

Definitions

  • the present invention relates to an antiviral agent.
  • antiviral agents having antiviral performance useful for control are desired.
  • An object of the present invention is to provide an antiviral agent having excellent antiviral performance.
  • the present inventor has arrived at the present invention as a result of diligent studies to solve such a problem. That is, the present invention (1) An antiviral agent containing the compound represented by the formula (I) as an active ingredient. M (C n H 2n-1 O 2 ) 2 (I) (N represents an integer of 6 to 10, and M represents Zn or ZrO.) (2) The above-mentioned antiviral agent containing zinc octylate as an active ingredient. (3) The above-mentioned antiviral agent further containing a powder having an oil absorption amount in the range of 1.5 to 5 mL / g measured by JIS K5101-13-1. (4) The above-mentioned antiviral agent in which the virus to be controlled is influenza virus and / or norovirus. (5) An antiviral processed product containing the above antiviral agent. I will provide a.
  • the antiviral agent according to the present invention contains a compound represented by the following formula (I) as an active ingredient.
  • M (C n H 2n-1 O 2 ) 2 (I) N represents an integer of 6 to 10, and M represents Zn or ZrO.)
  • the compound represented by the general formula (I) may have any of a linear structure, a branched structure and a cyclic structure. Specifically, for example, one or more selected from the group consisting of zinc octylate, zirconium octylate, zinc versaticate, and zirconium versaticate can be mentioned. Of these, zinc octylate is preferable.
  • the compound represented by the general formula (I) can be used as it is, but it is usually formulated by adding a solvent or the like.
  • the preparations include oils, emulsions, solubilized preparations, wettable powders, microcapsules, powders, tablets, aerosols, carbon dioxide gas preparations and the like.
  • Solvents used in the formulation include water, ethanol, isopropanol, phenoxyethanol, monovalent alcohols such as benzyl alcohol, ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, polypropylene glycol.
  • the compound represented by the general formula (I) When formulated as a powder, the compound represented by the general formula (I) may be supported on a powder having an oil absorption amount in the range of 1.5 to 5 mL / g as measured by JIS K5101-13-1. can.
  • powders include calcium silicate and silicon dioxide having the above-mentioned oil absorption, such as Fluorite (registered trademark) R, Fluorite (registered trademark) RT (manufactured by Tomita Pharmaceutical Co., Ltd.), and Toxile. (Registered trademark) NR (Oriental Calcium Corporation) and the like are commercially available.
  • the weight of the compound represented by the general formula (I) When supported on such powder, the weight of the compound represented by the general formula (I) is usually made to be four times or less the weight of the powder.
  • a surfactant a pH adjuster, a defoamer, a rust preventive, a viscosity adjuster, a metal sequestering agent, a light stabilizer, an ultraviolet absorber, an antibacterial agent, etc. may be added. These may be blended alone or in combination of two or more.
  • surfactants include polyoxyalkylene alkyl ethers, polyoxyalkylene allylphenyl ethers, block copolymers of polyoxyethylene and polyoxypropylene, glycerin fatty acid esters, sorbitan fatty acid esters, polyoxyalkylene sorbitan fatty acid esters, and polyoxyalkylene curing.
  • Nonionic surfactants such as castor oil, alkyl sulfate salts, alkyl ether sulfate salts, alkyl sulfosuccinate salts, alkyl sulfonate salts, alkyl allyl sulfonate salts, fatty acid amide sulfonate salts, lignin sulfonates, alkyl naphthalene sulfonates, alkyl Anionic surfactants such as phosphate salts, alkyl ether phosphate salts, naphthalene sulfonic acid formaldehyde condensate salts, cationic surfactants such as alkylamine salts and alkylammonium salts, and amphoteric surfactants such as glycine type, betaine type and imidazoline type. Can be mentioned.
  • the antiviral agent of the present invention is blended in a resin compound, a plastic agent such as a film or sheet, a coating agent such as a paint or a surface treatment agent, an adhesive, a woven fabric, a fiber such as a non-woven fabric, or a base material such as paper, and is an antivirus. It can be used as a processed product.
  • the blending amount of the antiviral agent is preferably 0.01 to 20 parts by weight with respect to 100 parts by weight of the base material of the antiviral processed product. Preferably, it is 0.1 to 10 parts by weight with respect to 100 parts by weight of the base material of the antiviral processed product.
  • living environment-related materials such as wall materials, handrails, floor materials, wooden floor materials, kitchen counters, furniture, and wallpaper, textile products such as refrigerator and air conditioner housings, and filters
  • textile products such as refrigerator and air conditioner housings, and filters
  • filters It is possible to impart antivirus performance to parts related to electrical products such as protective films for image displays of portable electronic devices, parts related to industrial products such as seats and floor mats for automobiles and trains, and parts related to packaging such as wrapping paper and corrugated cardboard. It becomes.
  • Antiviral performance means that even if a virus adheres, the virus infectivity decreases and it does not show infectivity.
  • the antiviral agent of the present invention is particularly effective against influenza virus and norovirus. Further, the antiviral agent of the present invention is expected to control viruses such as coronavirus, rhinovirus, RS virus, adenovirus and enterovirus.
  • parts mean parts by weight and% means% by weight.
  • Example 1 Zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., zinc octylate purity 99%) 20 parts, tarpen 16 parts, Leodor TW-O106V (manufactured by Kao Co., Ltd., polyoxyethylene sorbitan monooleate) 45 parts And 19 parts of water were mixed to obtain an antiviral agent (zinc octylate content: 19.8%).
  • Example 2 Zinc neodecanoate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) 20 parts, 16 parts of tarpen, 45 parts of Leodor TW-O106V and 19 parts of water were mixed to obtain an antiviral agent (zinc neodecanoate content: 19.8). %).
  • Example 3 Mix 36 parts of bis (2-ethylhexanoic acid) zirconium oxide (IV) mineral spirit solution (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., zirconium oxide purity 55%), 45 parts of Leodor TW-O106V and 19 parts of water. (The content of zirconium oxide octylate: 19.8%) was obtained.
  • Example 4 80 parts of zinc 2-ethylhexanoate (manufactured by Wako Pure Chemical Industries, Ltd., zinc octylate purity 99%) and 20 parts of Florite RT (oil absorption 4.2 mL / g) were mixed to obtain an antiviral agent. (Zinc content of zinc octylate: 79.2%).
  • Example 5 An antiviral agent was obtained by mixing 75 parts of zinc 2-ethylhexanoate (manufactured by Wako Pure Chemical Industries, Ltd., zinc octylate purity 99%) and 25 parts of Florite R (oil absorption 4.8 mL / g). (Zinc content of zinc octylate: 74.3%).
  • Comparative Example 1 A preparation was obtained by mixing 20 parts of zinc laurate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), 16 parts of tarpen, 45 parts of Leodor TW-O106V and 19 parts of water (zinc laurate content: 20%).
  • Comparative Example 2 A preparation was obtained by mixing 20 parts of zinc stearate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), 16 parts of tarpen, 45 parts of Leodor TW-O106V and 19 parts of water (zinc stearate content: 20%).
  • Comparative Example 3 16 parts of turpen, 45 parts of Leodor TW-O106V and 39 parts of water were mixed to obtain a pharmaceutical product.
  • feline calicivirus F-9 strain (Feline calicivirus, Strine: F-9 ATCC VR-782) was cultured with CRFK cells (feline kidney-derived cells), and the virus infectivity titer was 2 ⁇ 10 7 Plaque Forming Unit / mL (hereinafter).
  • PFU / mL test feline calicivirus suspension was obtained. It was diluted with sterile distilled water so that the concentration of the pharmaceutical product obtained in Example 1 was 5%. To 0.9 mL of this diluted solution, 0.1 mL of the above-mentioned test feline calicivirus suspension was added, and the mixture was allowed to stand at 25 ° C. for 2 hours.
  • Samples 2 to 6 having different dilution ratios were prepared by a serial dilution method in which E-MEM medium was added in an amount of 10 times, 100 times, 1000 times, 100,000 times, and 1,000,000 times to 0.1 mL of Sample 1.
  • the feline calicivirus infectious titer FCV infectious titer vs. numerical value
  • feline calicivirus F-9 strain feline calicivirus, Strine: F-9 ATCC VR-782 was used as influenza virus H3N2 strain (influenza A virus: A / Hong Kong / 8/68).
  • TC updated ATCC VR-1679 CRFK cells (feline kidney-derived cells) were changed to MDCK cells (canine kidney-derived cells), and the concentration of the diluent was changed from 5% to 1%, but the same procedure was performed.
  • the influenza virus infection titer IV infection titer vs. numerical value was measured in. The measurement results are shown in Table 2.
  • polyvinyl chloride sheet ZEST-1300 (polyvinyl chloride, manufactured by Shin Daiichi PVC Co., Ltd.) 100 parts, diisononyl phthalate 45 parts, epoxidized soybean oil 6.2 parts and LBK-793K (manufactured by Sakai Chemical Industry Co., Ltd.) 12.3 parts After mixing, the mixture was kneaded at 170 ° C. with a laboplast mill to obtain a vinyl chloride sol. A polyvinyl chloride sheet-0 was obtained by pressing this resin composition consisting of vinyl chloride only with a press molding machine heated to 180 ° C. for 3 minutes and then cooling the resin composition.
  • the antiviral test of the sheet was performed according to ISO21702. First, the above-mentioned polyvinyl chloride sheets-0, 1 and 2 were cut into 50 mm ⁇ 50 mm, respectively, to obtain test pieces. The test pieces were placed in a plastic petri dish, and 0.4 mL of the above-mentioned test feline calicivirus suspension was added dropwise to the substantially central region of each test piece. A 40 mm ⁇ 40 mm polyethylene film was placed so as to cover the entire virus suspension, and stored at 25 ° C. and 95% humidity for 24 hours.
  • test feline calicivirus suspension sandwiched between the test piece and the polyethylene film was washed out with SCDLP medium.
  • a dilution series of this wash-out solution was prepared by a serial dilution method using E-MEM medium.
  • the feline calicivirus infectious titer (FCV infectious titer vs. numerical value) of the obtained diluted solution was measured for CRFK cells by a plaque measurement method. The measurement results are shown in Table 3.
  • influenza virus infectious titer IV infectious titer vs. numerical value
  • Each of these resin compositions is applied to an aluminum bag with an applicator so as to have a concentration of 10 g / m 2, and then cured by irradiating with an ultraviolet ray of 350 mJ / cm 2 using an ultraviolet curing device HLR100T-2 (manufactured by AS ONE). I let you. Then, it was allowed to stand in a dryer at 60 ° C. for 24 hours to obtain an ultraviolet curable acrylic resin coating film (coating film ⁇ 0, 1, 2).
  • the antiviral test of the coating film was performed according to ISO21702. First, the above-mentioned coating films-0, 1 and 2 were cut into 50 mm ⁇ 50 mm, respectively, to obtain test pieces. The obtained test pieces were placed in a plastic petri dish, and 0.4 mL of the above-mentioned test feline calicivirus suspension was added dropwise to the substantially central region of each test piece. A 40 mm ⁇ 40 mm polyethylene film was placed so as to cover the entire virus suspension, and these were stored at 25 ° C. and 95% humidity for 24 hours.
  • test feline calicivirus suspension sandwiched between the test piece and the polyethylene film was washed out with SCDLP medium.
  • a dilution series of this wash-out solution was prepared by a serial dilution method using E-MEM medium.
  • the feline calicivirus infectious titer (FCV infectious titer vs. numerical value) of the obtained diluted solution was measured for CRFK cells by a plaque measurement method.
  • Table 4 shows the results of the antiviral test on the ultraviolet curable acrylic resin coating film.
  • Example 6 Zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., zinc octylate purity 99%) 70 parts, Naroacty (registered trademark) CL70 (polyoxyalkylene alkyl ether) (manufactured by Sanyo Kasei Kogyo Co., Ltd.) 30 parts was mixed to obtain an antiviral agent (zinc octylate content: 69.3%).
  • Naroacty registered trademark
  • CL70 polyoxyalkylene alkyl ether
  • Example 6 The formulation obtained in Example 6 was diluted with distilled water to prepare a dispersion. It was immersed in a standard cloth for antibacterial test (cotton distributed by the Textile Evaluation Technology Council) so that the supported amount of the preparation was 1.2 g / m 2 or 2.4 g / m 2. Then, it was dried at 105 degreeC to obtain processed fiber (processed fiber-1,2). Further, the above-mentioned standard cloth was immersed in distilled water and then dried at 105 ° C. to obtain a processed fiber (processed fiber-0) for comparison.
  • a standard cloth for antibacterial test cotton distributed by the Textile Evaluation Technology Council
  • Fibers were tested for antiviral properties according to ISO18184. First, the processed fibers-0, 1 and 2 were cut to a dry weight of 0.4 g and placed in a glass vial. After 0.2 mL of the above-mentioned test feline calicivirus suspension was added dropwise to each processed fiber so as to soak into the entire fiber, the cap was closed and the mixture was stored at 25 ° C. for 2 hours. Then, the feline calicivirus suspension was washed out by adding SCDLP medium to the vial and mixing well. A dilution series of this wash-out solution was prepared by a serial dilution method using E-MEM medium. The feline calicivirus infectious titer (FCV infectious titer vs. numerical value) of the obtained diluted solution was measured for CRFK cells by a plaque measurement method. The measurement results are shown in Table 5.
  • test virus was changed from cat calicivirus to influenza virus, and the influenza virus infectious titer (IV infectious titer vs. numerical value) was measured by a plaque measurement method for MDCK cells. The measurement results are shown in Table 5.
  • the antiviral agent of the present invention has excellent antiviral properties, wall materials, handrails, floor materials, wood floor materials, kitchen counters, furniture using antiviral processed products containing antiviral agents. , It is possible to impart antiviral performance to members related to the living environment such as wallpaper.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Materials Engineering (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2021/013255 2020-03-30 2021-03-29 抗ウイルス剤 Ceased WO2021200808A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022512202A JP7748103B2 (ja) 2020-03-30 2021-03-29 抗ウイルス剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-060618 2020-03-30
JP2020060618 2020-03-30

Publications (1)

Publication Number Publication Date
WO2021200808A1 true WO2021200808A1 (ja) 2021-10-07

Family

ID=77928977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/013255 Ceased WO2021200808A1 (ja) 2020-03-30 2021-03-29 抗ウイルス剤

Country Status (2)

Country Link
JP (1) JP7748103B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021200808A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023050045A (ja) * 2021-09-29 2023-04-10 住化エンバイロメンタルサイエンス株式会社 抗ウイルス剤およびそれを含む抗ウイルス加工品
JP2023165705A (ja) * 2021-06-15 2023-11-17 Dic株式会社 抗菌抗ウイルス剤、抗菌抗ウイルス性コーティング組成物、積層体、抗菌抗ウイルス性樹脂組成物および成形体
JP2024059262A (ja) * 2022-10-18 2024-05-01 Dic株式会社 抗菌抗ウイルス性樹脂組成物、硬化塗膜、積層体および成形体
JPWO2024128107A1 (cg-RX-API-DMAC7.html) * 2022-12-13 2024-06-20

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08269177A (ja) * 1995-03-29 1996-10-15 Nippon Shokubai Co Ltd 高分子量脂肪族ポリエステルの製造方法
JP2006514077A (ja) * 2003-01-13 2006-04-27 ザ プロクター アンド ギャンブル カンパニー 選抜された粘膜付着性ポリマーを含む、感冒及びインフルエンザ様の症状の予防及び治療のための組成物
JP2007510712A (ja) * 2003-11-11 2007-04-26 ベッキス インダストリーズ リミテッド 殺菌組成物ならびにその作製方法および使用方法
US20090018213A1 (en) * 2006-02-09 2009-01-15 Marcia Snyder Antiviral method
JP2015078479A (ja) * 2013-09-10 2015-04-23 ライオン株式会社 繊維製品のウイルス除去方法
JP2015523441A (ja) * 2012-07-05 2015-08-13 スリーエム イノベイティブ プロパティズ カンパニー 硬化性抗菌性組成物
CN109796700A (zh) * 2019-01-25 2019-05-24 南通壹选工业设计有限公司 高透明的医用pvc塑料

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4526622B2 (ja) * 1998-10-23 2010-08-18 北興化学工業株式会社 農園芸用種子消毒剤および種子の消毒方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08269177A (ja) * 1995-03-29 1996-10-15 Nippon Shokubai Co Ltd 高分子量脂肪族ポリエステルの製造方法
JP2006514077A (ja) * 2003-01-13 2006-04-27 ザ プロクター アンド ギャンブル カンパニー 選抜された粘膜付着性ポリマーを含む、感冒及びインフルエンザ様の症状の予防及び治療のための組成物
JP2007510712A (ja) * 2003-11-11 2007-04-26 ベッキス インダストリーズ リミテッド 殺菌組成物ならびにその作製方法および使用方法
US20090018213A1 (en) * 2006-02-09 2009-01-15 Marcia Snyder Antiviral method
JP2015523441A (ja) * 2012-07-05 2015-08-13 スリーエム イノベイティブ プロパティズ カンパニー 硬化性抗菌性組成物
JP2015078479A (ja) * 2013-09-10 2015-04-23 ライオン株式会社 繊維製品のウイルス除去方法
CN109796700A (zh) * 2019-01-25 2019-05-24 南通壹选工业设计有限公司 高透明的医用pvc塑料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SASAHARA, TAKESHI: "Report on Research Results by the Japan Mining Promotion Association Research Grant (part 3)", vol. 49, no. 3, 2012, pages 24 - 27 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023165705A (ja) * 2021-06-15 2023-11-17 Dic株式会社 抗菌抗ウイルス剤、抗菌抗ウイルス性コーティング組成物、積層体、抗菌抗ウイルス性樹脂組成物および成形体
JP2023050045A (ja) * 2021-09-29 2023-04-10 住化エンバイロメンタルサイエンス株式会社 抗ウイルス剤およびそれを含む抗ウイルス加工品
JP7690199B2 (ja) 2021-09-29 2025-06-10 住化エンバイロメンタルサイエンス株式会社 抗ウイルス剤およびそれを含む抗ウイルス加工品
JP2024059262A (ja) * 2022-10-18 2024-05-01 Dic株式会社 抗菌抗ウイルス性樹脂組成物、硬化塗膜、積層体および成形体
JPWO2024128107A1 (cg-RX-API-DMAC7.html) * 2022-12-13 2024-06-20
WO2024128107A1 (ja) * 2022-12-13 2024-06-20 Dic株式会社 マスターバッチ、樹脂組成物、成形体およびそれらの製造方法
JP7786617B2 (ja) 2022-12-13 2025-12-16 Dic株式会社 マスターバッチ、樹脂組成物、成形体およびそれらの製造方法

Also Published As

Publication number Publication date
JPWO2021200808A1 (cg-RX-API-DMAC7.html) 2021-10-07
JP7748103B2 (ja) 2025-10-02

Similar Documents

Publication Publication Date Title
JP7748103B2 (ja) 抗ウイルス剤
EP2997051B2 (de) Superabsorbierende polymere mit schnellen absorptionseigenschaften sowie verfahren zu dessen herstellung
JP6314211B2 (ja) 高吸収性を有する超吸収性ポリマー及びその製造方法
EP1824889B1 (de) Verfahren zur nachvernetzung wasserabsorbierender polymerpartikel
CN109415455B (zh) N-乙烯基内酰胺系交联聚合物、化妆料、油墨用吸收剂和吸收性复合体
CN102046186A (zh) 抗微生物和抗静电聚合物以及在各种基材上使用这些聚合物的方法
JP2014533312A (ja) 高吸収性を有する超吸収性ポリマー及びその製造方法
DE102005002412A1 (de) Verfahren zur Herstellung von Polymeren durch Sprühpolymerisation
JP2017014509A (ja) 殺菌・抗ウイルス性を有するセルロースナノファイバー
EP2709682A1 (de) Verwendung wasserabsorbierender polymerpartikel zur absorption von blut und/oder menstruationsflüssigkeit
JP7224022B2 (ja) 抗ウイルス組成物
EP3510193A1 (en) Method for making fluorocarbon free emulsions without using traditional surfactants/emulsifiers by emulsifying alkoxysilanes or other non-water soluble hydrophobizing agents using amino functional siloxanes and the uses thereof
JP3230381B2 (ja) フッ素系ポリマー水性分散液
JP2025154153A (ja) 抗ウイルス剤
JP7690199B2 (ja) 抗ウイルス剤およびそれを含む抗ウイルス加工品
WO2022072394A1 (en) Curable coating compositions and antimicrobial/antiviral coatings made by curing such coating compositions
JP5114692B2 (ja) 抗アレルゲン組成物およびアレルゲン低減化方法
KR101781105B1 (ko) 항바이러스 조성물
JP2022080892A (ja) 抗ウイルス性組成物
JPS6348202A (ja) 殺微生物組成物
JP2023013113A (ja) 抗ウイルス性組成物
DE69507818T2 (de) Topisches wässriges hautpflegemittel enthaltend ein hydrogel-eindicker und ein wasserunlösliche silikonkonditionierungsagens
JP6630903B2 (ja) 抗菌粉体組成物
JP7710715B2 (ja) 抗菌性または抗ウイルス性組成物
MXPA03001519A (es) Preparar articulos esteriles de polimeros que contienen un estabilizador basado en un poli (oxialquileno).

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21778953

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022512202

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21778953

Country of ref document: EP

Kind code of ref document: A1